The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
1. A composition comprising an immunostimulatory effective amount of aluminum hydroxide adjuvant and a substantially purified polypeptide comprising
a fragment of an amino acid sequence of SEQ ID NO: 1200, 1202, or 1204, wherein said fragment comprises 14 or more consecutive amino acids from said amino acid sequence and wherein the fragment does not comprise the N-terminal leader sequence MFKRSVIAMACIFPLSA (SEQ ID NO: 4169), if the fragment comprises 14 or more consecutive amino acids from the amino acid sequence of SEQ ID NO: 1200; the fragment does not comprise the N-terminal leader sequence MFKRSVIAMACIFALSA (SEQ ID NO: 4170), if the fragment comprises 14 or more consecutive amino acids from the amino acid sequence of SEQ ID NO: 1202; or the fragment does not comprise the N-terminal leader sequence MFKRSVIAMACIVALSA (SEQ ID NO: 4171), if the fragment comprises 14 or more consecutive amino acids from the amino acid sequence of SEQ ID NO: 1204.
2. The composition of claim 1 wherein the substantially purified polypeptide is immunogenic.
3. The composition of claim 1 further comprising a pharmaceutically acceptable excipient.
4. The composition of claim 1 wherein the fragment comprises 16 or more consecutive amino acids from said amino acid sequence.
5. The composition of claim 1 wherein the fragment comprises 18 or more consecutive amino acids from said amino acid sequence.
6. The composition of claim 1 wherein the fragment comprises 20 or more consecutive amino acids from said amino acid sequence.
7. The composition of claim 4 further comprising a pharmaceutically acceptable excipient.
8. The composition of claim 5 further comprising a pharmaceutically acceptable excipient.
9. The composition of claim 6 further comprising a pharmaceutically acceptable excipient.